Dr. Kayce M. Morton

Hospital Medicine | Pediatrics
10 Water St, 
Waterville, ME 
Accepting New Patients
10 Water St, 
Waterville, ME 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Kayce Morton is a Hospital Medicine specialist and a Pediatrics provider in Waterville, Maine. Dr. Morton is currently accepting new patients.

Her clinical research consists of co-authoring 8 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hospital Medicine
Pediatrics
Licenses
Pediatrics in MO
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Cox Health
  • EPO
  • PPO
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 4 Less Insurance Carriers -

Locations

10 Water St, Waterville, ME 04901

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Phase 1, Open-Label, Randomized Study to Evaluate Safety and Pharmacokinetics of Anti-SARS-CoV-2 Immunoglobulin (Human) Investigational Product (COVID-HIG) Administered Through Intramuscular, Subcutaneous or Intravenous Routes as a Single Dose Regimen to SARS-CoV-2 Uninfected Adults
A Phase 1, Open-Label, Randomized Study to Evaluate Safety and Pharmacokinetics of Anti-SARS-CoV-2 Immunoglobulin (Human) Investigational Product (COVID-HIG) Administered Through Intramuscular, Subcutaneous or Intravenous Routes as a Single Dose Regimen to SARS-CoV-2 Uninfected Adults
Enrollment Status: Completed
Publish Date: June 08, 2025
Intervention Type: Biological
Study Phase: Phase 1
A Randomized, Double-blind, Placebo-Controlled, Phase 2/3 Study to Evaluate the Efficacy and Safety of LY3819253 and LY3832479 in Participants With Mild to Moderate COVID-19 Illness
A Randomized, Double-blind, Placebo-Controlled, Phase 2/3 Study to Evaluate the Efficacy and Safety of LY3819253 and LY3832479 in Participants With Mild to Moderate COVID-19 Illness
Enrollment Status: Completed
Publish Date: April 11, 2024
Intervention Type: Drug
Study Drugs: Bamlanivimab, Etesevimab
Study Phase: Phase 2/Phase 3
Phase 1, Open-label, Parallel, 2-arm, Fixed-sequence Study to Investigate the Effect of Coadministration of CYP3A4 Inhibitor and CYP3A4 Inducer on the Pharmacokinetics, Safety, and Tolerability of KBP-5074 in Healthy Subjects
Phase 1, Open-label, Parallel, 2-arm, Fixed-sequence Study to Investigate the Effect of Coadministration of CYP3A4 Inhibitor and CYP3A4 Inducer on the Pharmacokinetics, Safety, and Tolerability of KBP-5074 in Healthy Subjects
Enrollment Status: Completed
Publish Date: February 23, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Mono and Combination Therapy With Monoclonal Antibodies in Participants With Mild to Moderate COVID-19 Illness (BLAZE-4)
A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Mono and Combination Therapy With Monoclonal Antibodies in Participants With Mild to Moderate COVID-19 Illness (BLAZE-4)
Enrollment Status: Completed
Publish Date: July 01, 2022
Intervention Type: Drug
Study Drugs: Bamlanivimab, Etesevimab, LY3853113 Anti-COVID-19 Antibody, VIR-7831 Anti-COVID-19 Antibody
Study Phase: Phase 2
A Randomized, Multi-Center, Open-Label, Parallel-Cohort Study to Characterize Product Use in Smokers Switching From Combustible Cigarettes to a RELX Electronic Nicotine Delivery System (ENDS)
A Randomized, Multi-Center, Open-Label, Parallel-Cohort Study to Characterize Product Use in Smokers Switching From Combustible Cigarettes to a RELX Electronic Nicotine Delivery System (ENDS)
Enrollment Status: Completed
Publish Date: July 22, 2021
Intervention Type: Other
Study Phase: Not Applicable
CSD190103: An Unblinded, Randomized, Multi-site, Two-way Crossover Study to Assess Nicotine Pharmacokinetic Parameters After Use of Two Smokeless Tobacco Products A19010-W and B19010-F in Healthy Adult Snus Consumers.
CSD190103: An Unblinded, Randomized, Multi-site, Two-way Crossover Study to Assess Nicotine Pharmacokinetic Parameters After Use of Two Smokeless Tobacco Products A19010-W and B19010-F in Healthy Adult Snus Consumers.
Enrollment Status: Completed
Publish Date: October 25, 2019
Intervention Type: Other
Study Phase: Not Applicable
CSD190102: An Unblinded, Randomized, Multi-site, Two-way Crossover Study to Assess Nicotine Pharmacokinetic Parameters After Use of Two Smokeless Tobacco Products A19010-R and B19010-O in Healthy Adult Snus Consumers.
CSD190102: An Unblinded, Randomized, Multi-site, Two-way Crossover Study to Assess Nicotine Pharmacokinetic Parameters After Use of Two Smokeless Tobacco Products A19010-R and B19010-O in Healthy Adult Snus Consumers.
Enrollment Status: Completed
Publish Date: October 25, 2019
Intervention Type: Other
Study Phase: Not Applicable
CSD190101: An Unblinded, Randomized, Multi-site, Two-way Crossover Study to Assess Nicotine Pharmacokinetic Parameters After Use of Two Smokeless Tobacco Products A19010-F and B19010-F in Healthy Adult Snus Consumers.
CSD190101: An Unblinded, Randomized, Multi-site, Two-way Crossover Study to Assess Nicotine Pharmacokinetic Parameters After Use of Two Smokeless Tobacco Products A19010-F and B19010-F in Healthy Adult Snus Consumers.
Enrollment Status: Completed
Publish Date: October 25, 2019
Intervention Type: Other
Study Phase: Not Applicable
View 7 Less Clinical Trials

8 Total Publications

Pediatric Randomized Clinical Trials in Community Hospitals: Strategies to Enhance Site Participation and Engagement.
Pediatric Randomized Clinical Trials in Community Hospitals: Strategies to Enhance Site Participation and Engagement.
Journal: Hospital pediatrics
Published: October 14, 2024
Similar Doctors
Expertise in
1
conditions
Dr. Terry R. Allen
Hospital Medicine
Expertise in
1
conditions
Dr. Terry R. Allen
Hospital Medicine

Eastern Maine Medical Center

489 State St, 
Bangor, ME 
 (45.8 miles away)
207-973-7000
Languages Spoken:
English
See accepted insurances

Terry Allen is a Hospital Medicine provider in Bangor, Maine. Dr. Allen is highly rated in 1 condition, according to our data. His top area of expertise is End-Stage Renal Disease (ESRD).

Expertise in
47
conditions
Dr. Khurram Nazir
Neurology | Hospital Medicine
Expertise in
47
conditions
Dr. Khurram Nazir
Neurology | Hospital Medicine

St Joseph Hospital

360 Broadway, 
Bangor, ME 
 (46.0 miles away)
Languages Spoken:
English, Hindi, Punjabi, Urdu
See accepted insurances
Accepting New Patients
Offers Telehealth

Khurram Nazir is a Neurologist and a Hospital Medicine provider in Bangor, Maine. Dr. Nazir is highly rated in 47 conditions, according to our data. His top areas of expertise are Seizures, Generalized Tonic-Clonic Seizure, Chronic Pain, and Stroke. Dr. Nazir is currently accepting new patients.

Expertise in
10
conditions
Dr. Timothy J. Borelli
Infectious Disease | Hospital Medicine
Expertise in
10
conditions
Dr. Timothy J. Borelli
Infectious Disease | Hospital Medicine

Mainegeneral Medical Center

149 N St, 
Waterville, ME 
 (1.5 miles away)
207-872-1000
Languages Spoken:
English
See accepted insurances

Timothy Borelli is an Infectious Disease specialist and a Hospital Medicine provider in Waterville, Maine. Dr. Borelli is highly rated in 10 conditions, according to our data. His top areas of expertise are Infectious Arthritis, Neurosyphilis, Osteomyelitis, and Ehrlichiosis.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Morton's expertise for a condition
ConditionClose

We do not have enough information to identify the Areas of Expertise for this provider.

Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile